TMS as a pharmacodynamic indicator of cortical activity of a novel anti-epileptic drug, XEN1101.

Isabella PremoliPierre G RossiniPaul Y GoldbergKristina PosadasLouise GreenNoah YogoSimon PimstoneEugenio AbelaGregory N BeatchMark P Richardson

Published in: Annals of clinical and translational neurology (2019)

Changes from baseline in TMS measures provided evidence that 20 mg of XEN1101 suppressed cortical and corticospinal excitability, consistent with the effects of other AEDs. These results support the implementation of TMS as a tool to inform early-stage clinical trials.

Keyphrases

transcranial magnetic stimulation
high frequency
early stage
clinical trial
primary care
healthcare
quality improvement
transcranial direct current stimulation
radiation therapy
adverse drug
lymph node